Recombinant Human B7-DC /PD-L2 /CD273 Protein, His tag, (SPR verified), 100µg

Background
Programmed cell death 1 ligand 2 (PD-L2 or PDCD1 ligand 2) is also known as Butyrophilin B7-DC, CD antigen CD273, which belongs to the immunoglobulin superfamily or BTN/MOG family. The expression of PD-L2 is up-regulated by IFNG/IFN-gamma stimulation in monocytes and induced on dendritic cells grown from peripheral blood mononuclear cells with CSF2 and IL-4. PD-L2 Involved in the costimulatory signal, essential for T-cell proliferation and IFNG production in a PDCD1-independent manner. PD-L2 interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production.

Source
Recombinant Human PD-L2, His Tag (SPR verified) (PD2-H5220) is expressed from human 293 cells (HEK293). It contains AA Leu 20 - Pro 219 (Accession # AAI13679). Predicted N-terminus: Leu 20

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 23.4 kDa. The protein migrates as 34-46 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg of the rh B7-DC / PD-L2 / CD273 by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Periodontal Disease Augments Cardiovascular Disease Risk Biomarkers in Rheumatoid Arthritis"
Panezai, Ghaffar, Altamash et al
Biomedicines (2022) 10 (3)
(2) "Expression of PD-1, PD-L1 and PD-L2 in Lymphomas in Patients with Pre-Existing Rheumatic Diseases-A Possible Association with High Rheumatoid Arthritis Disease Activity"
Hellbacher, Sundström, Molin et al
Cancers (Basel) (2022) 14 (6)
(3) "Gene expression trend changes in breast cancer populations over two decades: insights from The Cancer Genome Atlas database"
Wu, Liu, Hu et al
Hereditas (2022) 159 (1), 18
Showing 1-3 of 1267 papers.

Citations

(1) "Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy"
Authors: Fromm G, et al
Journal: J ImmunoTher Cancer 43452
Application: SPR